Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

Melody Hermel; Andrew Chiou; Abdul Mannan Khan Minhas; Maha Inam; Carly E. Waldman; Eventine Youngblood; Sandeep Mehta; Leandro Slipczuk; Sana Sheikh; Chelsea Meloche; Adeel Khoja; Salim S. Virani

doi:10.1007/s11883-024-01193-8

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

Melody Hermel
, Andrew Chiou
, Abdul Mannan Khan Minhas
, Maha Inam
, Carly E. Waldman
, Eventine Youngblood
, Sandeep Mehta
, Leandro Slipczuk
, Sana Sheikh
, Chelsea Meloche
, Adeel Khoja
, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

Original language	English (US)
Pages (from-to)	119-131
Number of pages	13
Journal	Current Atherosclerosis Reports
Volume	26
Issue number	4
DOIs	https://doi.org/10.1007/s11883-024-01193-8
Publication status	Published - Apr 2024

Keywords

Acute coronary syndrome
Cardiovascular disease
Dapagliflozin
Hyperlipidemia
Prevention
Semaglutide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11883-024-01193-8

Cite this

Hermel, M., Chiou, A., Minhas, A. M. K., Inam, M., Waldman, C. E., Youngblood, E., Mehta, S., Slipczuk, L., Sheikh, S., Meloche, C., Khoja, A., & Virani, S. S. (2024). Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. Current Atherosclerosis Reports, 26(4), 119-131. https://doi.org/10.1007/s11883-024-01193-8

@article{aa52ed0f4f444bb6b62e8cfe572c10c2,

title = "Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions",

abstract = "Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.",

keywords = "Acute coronary syndrome, Cardiovascular disease, Dapagliflozin, Hyperlipidemia, Prevention, Semaglutide",

author = "Melody Hermel and Andrew Chiou and Minhas, \{Abdul Mannan Khan\} and Maha Inam and Waldman, \{Carly E.\} and Eventine Youngblood and Sandeep Mehta and Leandro Slipczuk and Sana Sheikh and Chelsea Meloche and Adeel Khoja and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.",

year = "2024",

month = apr,

doi = "10.1007/s11883-024-01193-8",

language = "English (US)",

volume = "26",

pages = "119--131",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer",

number = "4",

}

Hermel, M, Chiou, A, Minhas, AMK, Inam, M, Waldman, CE, Youngblood, E, Mehta, S, Slipczuk, L, Sheikh, S, Meloche, C, Khoja, A & Virani, SS 2024, 'Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions', Current Atherosclerosis Reports, vol. 26, no. 4, pp. 119-131. https://doi.org/10.1007/s11883-024-01193-8

TY - JOUR

T1 - Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

AU - Hermel, Melody

AU - Chiou, Andrew

AU - Minhas, Abdul Mannan Khan

AU - Inam, Maha

AU - Waldman, Carly E.

AU - Youngblood, Eventine

AU - Mehta, Sandeep

AU - Slipczuk, Leandro

AU - Sheikh, Sana

AU - Meloche, Chelsea

AU - Khoja, Adeel

AU - Virani, Salim S.

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.

PY - 2024/4

Y1 - 2024/4

N2 - Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

AB - Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

KW - Acute coronary syndrome

KW - Cardiovascular disease

KW - Dapagliflozin

KW - Hyperlipidemia

KW - Prevention

KW - Semaglutide

UR - https://www.scopus.com/pages/publications/85186613187

U2 - 10.1007/s11883-024-01193-8

DO - 10.1007/s11883-024-01193-8

M3 - Review article

AN - SCOPUS:85186613187

SN - 1523-3804

VL - 26

SP - 119

EP - 131

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 4

ER -

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this